Want to see TSE:NEVI full AI Analyst Report?
Top Page
Pascal Biosciences Inc
(NEVI)
Select Model
Select Model
Rating:45Neutral
Price Target:
C$0.02
▲(20.00% Upside)
Action:Reiterated
Date:09/07/26
The score is held back primarily by weak financial performance (sharp revenue contraction and ongoing losses) and bearish technicals (below key moving averages with negative MACD). Improving cash flow and a stabilized balance sheet provide some support, but valuation remains unattractive due to negative earnings and no dividend support.
Positive Factors
Manageable Leverage
Manageable leverage and positive equity provide a more stable financial base than the company had in earlier periods. This should preserve flexibility to fund operations and address business needs, although the benefit remains constrained while profitability and shareholder returns are negative.
Negative Factors
Sharp Revenue Contraction
A sharply contracting top line weakens the company’s ability to spread fixed costs, invest in growth, and build a durable earnings base. Continued revenue pressure could offset margin improvements and keep the business dependent on cost controls rather than sustainable expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable Leverage
Manageable leverage and positive equity provide a more stable financial base than the company had in earlier periods. This should preserve flexibility to fund operations and address business needs, although the benefit remains constrained while profitability and shareholder returns are negative.
Read all positive factors
Pascal Biosciences Inc (NEVI) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$793.25K
Dividend YieldN/A
Average Volume (3M)42.92K
Price to Earnings (P/E)―
Beta (1Y)1.53
Revenue Growth9.40%
EPS Growth25.81%
CountryCA
Employees2
SectorConsumer Defensive
Sector Strength42
IndustryBeverages - Non-Alcoholic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding39,662,727
10 Day Avg. Volume63,112
30 Day Avg. Volume42,919
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.05
Price to Sales (P/S)1.17
P/FCF Ratio31.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pascal Biosciences Inc Business Overview & Revenue Model
Company Description
Nevis Brands Inc. engages in the development and sale of cannabis products in the United States. It offers hemp derived THC beverages under the Major brand name. The company was formerly known as Pascal Biosciences Inc. and changed its name to Nev...
Pascal Biosciences Inc Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
52
Neutral
Cash Flow
57
Neutral
| Breakdown | TTM | Nov 2025 | Feb 2025 | Feb 2024 | Nov 2022 | Feb 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.66M | 1.70M | 1.55M | 671.54K | 0.00 | 0.00 |
| Gross Profit | 622.70K | 396.31K | 1.08M | 392.94K | -8.29K | -16.32K |
| EBITDA | -32.62K | -32.66K | -48.07K | -271.56K | -468.09K | -1.07M |
| Net Income | -348.97K | -275.07K | -362.48K | -399.77K | -480.28K | -1.09M |
Balance Sheet | ||||||
| Total Assets | 1.49M | 1.72M | 2.04M | 2.50M | 18.82K | 155.19K |
| Cash, Cash Equivalents and Short-Term Investments | 60.85K | 102.17K | 129.54K | 418.52K | 8.37K | 0.00 |
| Total Debt | 394.63K | 244.21K | 528.30K | 683.27K | 224.62K | 7.76K |
| Total Liabilities | 621.16K | 746.36K | 813.50K | 1.12M | 962.93K | 646.48K |
| Stockholders Equity | 872.36K | 968.95K | 1.23M | 1.38M | -944.11K | -491.30K |
Cash Flow | ||||||
| Free Cash Flow | 93.88K | 62.10K | -132.06K | -390.49K | -147.68K | -614.93K |
| Operating Cash Flow | 93.88K | 62.10K | -120.50K | -385.35K | -147.68K | -614.93K |
| Investing Cash Flow | 0.00 | 0.00 | -11.56K | -947.71K | 8.98K | 0.00 |
| Financing Cash Flow | -89.94K | -90.20K | -167.65K | 1.76M | 154.84K | 624.08K |
Pascal Biosciences Inc Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.02
Negative
0.03
Negative
Market Momentum
>-0.01
Negative
43.70
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NEVI, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.70 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:NEVI.
Pascal Biosciences Inc Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | C$1.89M | 11.90 | 0.38% | ― | -87.74% | -220.61% | |
45 Neutral | C$793.25K | -3.17 | -26.77% | ― | 9.40% | 25.81% | |
41 Neutral | C$441.11K | -0.67 | 30.06% | ― | -3.70% | 51.27% |
* Consumer Defensive Sector Average
TSE:NEVI
Pascal Biosciences Inc
0.02
-0.03
-60.00%
TSE:TAAT
TAAT Global Alternatives
0.18
0.00
0.00%
TSE:MEAT
Modern Meat
0.06
-0.06
-50.00%
TSE:LFST
Lifeist Wellness
0.05
-0.02
-33.33%
TSE:MUSL
Element Nutritional Sciences Inc
0.03
-0.02
-40.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.